284 related articles for article (PubMed ID: 19710597)
21. Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice.
Zhou M; Kostoula I; Brill B; Panou E; Sakarellos-Daitsiotis M; Dietrich U
Vaccine; 2012 Mar; 30(11):1911-6. PubMed ID: 22269872
[TBL] [Abstract][Full Text] [Related]
22. Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions.
Dennison SM; Stewart SM; Stempel KC; Liao HX; Haynes BF; Alam SM
J Virol; 2009 Oct; 83(19):10211-23. PubMed ID: 19640992
[TBL] [Abstract][Full Text] [Related]
23. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.
Nelson JD; Brunel FM; Jensen R; Crooks ET; Cardoso RM; Wang M; Hessell A; Wilson IA; Binley JM; Dawson PE; Burton DR; Zwick MB
J Virol; 2007 Apr; 81(8):4033-43. PubMed ID: 17287272
[TBL] [Abstract][Full Text] [Related]
24. Both lipid environment and pH are critical for determining physiological solution structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER peptide P1.
Coutant J; Yu H; Clément MJ; Alfsen A; Toma F; Curmi PA; Bomsel M
FASEB J; 2008 Dec; 22(12):4338-51. PubMed ID: 18776068
[TBL] [Abstract][Full Text] [Related]
25. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.
Luo M; Yuan F; Liu Y; Jiang S; Song X; Jiang P; Yin X; Ding M; Deng H
Vaccine; 2006 Jan; 24(4):435-42. PubMed ID: 16143433
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.
Banerjee S; Shi H; Banasik M; Moon H; Lees W; Qin Y; Harley A; Shepherd A; Cho MW
Virology; 2017 May; 505():113-126. PubMed ID: 28237764
[TBL] [Abstract][Full Text] [Related]
27. Characterization of a trimeric MPER containing HIV-1 gp41 antigen.
Hinz A; Schoehn G; Quendler H; Hulsik DL; Stiegler G; Katinger H; Seaman MS; Montefiori D; Weissenhorn W
Virology; 2009 Aug; 390(2):221-7. PubMed ID: 19539967
[TBL] [Abstract][Full Text] [Related]
28. Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope.
Li J; Chen X; Jiang S; Chen YH
Biochem Biophys Res Commun; 2008 Nov; 376(1):60-4. PubMed ID: 18762167
[TBL] [Abstract][Full Text] [Related]
29. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.
Guenaga J; Wyatt RT
PLoS Pathog; 2012; 8(7):e1002806. PubMed ID: 22829767
[TBL] [Abstract][Full Text] [Related]
30. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
Julien JP; Bryson S; Nieva JL; Pai EF
J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
[TBL] [Abstract][Full Text] [Related]
31. Generation of HIV-1 potent and broad neutralizing antibodies by immunization with postfusion HR1/HR2 complex.
Dawood R; Benjelloun F; Pin JJ; Kone A; Chanut B; Jospin F; Lucht F; Verrier B; Moog C; Genin C; Paul S
AIDS; 2013 Mar; 27(5):717-30. PubMed ID: 23719346
[TBL] [Abstract][Full Text] [Related]
32. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb.
McGaughey GB; Citron M; Danzeisen RC; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller M; Shiver J; Bogusky MJ
Biochemistry; 2003 Mar; 42(11):3214-23. PubMed ID: 12641452
[TBL] [Abstract][Full Text] [Related]
33. The Use of Liposomes to Shape Epitope Structure and Modulate Immunogenic Responses of Peptide Vaccines Against HIV MPER.
Apellániz B; Nieva JL
Adv Protein Chem Struct Biol; 2015; 99():15-54. PubMed ID: 26067815
[TBL] [Abstract][Full Text] [Related]
34. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.
Ye L; Wen Z; Dong K; Wang X; Bu Z; Zhang H; Compans RW; Yang C
PLoS One; 2011; 6(5):e14813. PubMed ID: 21625584
[TBL] [Abstract][Full Text] [Related]
35. Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.
Ma BJ; Alam SM; Go EP; Lu X; Desaire H; Tomaras GD; Bowman C; Sutherland LL; Scearce RM; Santra S; Letvin NL; Kepler TB; Liao HX; Haynes BF
PLoS Pathog; 2011 Sep; 7(9):e1002200. PubMed ID: 21909262
[TBL] [Abstract][Full Text] [Related]
36. Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies.
Zhai Y; Zhong Z; Zariffard M; Spear GT; Qiao L
Vaccine; 2013 Nov; 31(46):5422-9. PubMed ID: 24055348
[TBL] [Abstract][Full Text] [Related]
37. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1.
Matyas GR; Beck Z; Karasavvas N; Alving CR
Biochim Biophys Acta; 2009 Mar; 1788(3):660-5. PubMed ID: 19100711
[TBL] [Abstract][Full Text] [Related]
38. An Engineered Biomimetic MPER Peptide Vaccine Induces Weakly HIV Neutralizing Antibodies in Mice.
Shao S; Huang WC; Lin C; Hicar MD; LaBranche CC; Montefiori DC; Lovell JF
Ann Biomed Eng; 2020 Jul; 48(7):1991-2001. PubMed ID: 31832930
[TBL] [Abstract][Full Text] [Related]
39. Selection and immune recognition of HIV-1 MPER mimotopes.
Wieczorek L; Peachman K; Steers N; Schoen J; Rao M; Polonis V; Rao V
Virology; 2020 Nov; 550():99-108. PubMed ID: 32980676
[TBL] [Abstract][Full Text] [Related]
40. Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane.
Montero M; Gulzar N; Klaric KA; Donald JE; Lepik C; Wu S; Tsai S; Julien JP; Hessell AJ; Wang S; Lu S; Burton DR; Pai EF; Degrado WF; Scott JK
J Virol; 2012 Mar; 86(6):2930-41. PubMed ID: 22238313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
